Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial. - Tariot PN; Lopera FS; Ríos-Romenets S; Sink KM; Giraldo-Chica M; Acosta-Baena N; Villegas G; Espinosa A; Castaño ML; Muñoz C; Ospina P; Bocanegra Y; et al. (The Lancet. Neurology, 2026)